Rebif and Red blood cell count decreased - a phase IV clinical study of FDA data

Summary:

Red blood cell count decreased is found among people who take Rebif, especially for people who are female, 50-59 old, have been taking the drug for 1 - 2 years.

The phase IV clinical study analyzes which people take Rebif and have Red blood cell count decreased. It is created by eHealthMe based on reports of 58,459 people who have side effects when taking Rebif from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 07, 2023

58,459 people reported to have side effects when taking Rebif.
Among them, 188 people (0.32%) have Red blood cell count decreased.

What is Rebif?

Rebif has active ingredients of interferon beta-1a. It is often used in multiple sclerosis. eHealthMe is studying from 58,748 Rebif users for its effectiveness, alternative drugs and more.

What is Red blood cell count decreased?

Red blood cell count decreased is found to be associated with 2,232 drugs and 1,728 conditions by eHealthMe.

Number of Rebif and Red blood cell count decreased reports submitted per year:

Could Rebif cause Red blood cell count decreased?

* Approximation only. Some reports may have incomplete information.

Do you take Rebif and have Red blood cell count decreased?

Check whether Red blood cell count decreased is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Red blood cell count decreased and when was it recovered:

Red blood cell count decreased in Rebif

Expand to all the drugs that have ingredients of interferon beta-1a:

Red blood cell count decreased and drugs with ingredients of interferon beta-1a

Alternative drugs to, pros and cons of Rebif:

Rebif (58,748 reports)

Common Rebif side effects:

Fatigue (feeling of tiredness): 4,021 reports
Weakness: 3,450 reports
Headache (pain in head): 3,244 reports
Pain: 2,606 reports
Urinary tract infection: 2,548 reports

Browse all side effects of Rebif:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Red blood cell count decreased treatments and more:

Red blood cell count decreased (33,146 reports)

COVID vaccines that are related to Red blood cell count decreased:

Common drugs associated with Red blood cell count decreased:

All the drugs that are associated with Red blood cell count decreased:

Red blood cell count decreased (2,232 drugs)

Common conditions associated with Red blood cell count decreased:

Multiple myeloma: 2,208 reports
Hepatitis c: 1,948 reports
High blood pressure: 1,542 reports
Rheumatoid arthritis: 1,434 reports
Ovarian cancer: 1,355 reports

All the conditions that are associated with Red blood cell count decreased:

Red blood cell count decreased (1,728 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on interferon beta-1a (the active ingredients of Rebif) and Rebif (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.